VanEck Associates’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $76K | Buy |
2,101
+308
| +17% | +$11.1K | ﹤0.01% | 1313 |
|
|
2025
Q1 | $65K | Buy |
1,793
+33
| +2% | +$1.2K | ﹤0.01% | 1297 |
|
|
2024
Q4 | $74K | Buy |
1,760
+273
| +18% | +$11.5K | ﹤0.01% | 1283 |
|
|
2024
Q3 | $81K | Sell |
1,487
-457
| -24% | -$24.9K | ﹤0.01% | 1261 |
|
|
2024
Q2 | $80K | Buy |
1,944
+36
| +2% | +$1.48K | ﹤0.01% | 1264 |
|
|
2024
Q1 | $89K | Buy |
1,908
+330
| +21% | +$15.4K | ﹤0.01% | 1241 |
|
|
2023
Q4 | $75K | Buy |
1,578
+400
| +34% | +$19K | ﹤0.01% | 1261 |
|
|
2023
Q3 | $42K | Buy |
1,178
+29
| +3% | +$1.03K | ﹤0.01% | 1296 |
|
|
2023
Q2 | $53K | Buy |
+1,149
| New | +$53K | ﹤0.01% | 1300 |
|